ADMA BIOLOGICS INC (ADMA) Stock Price, Quote, News and Overview
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA Quote, Performance and Key Statistics
ADMA BIOLOGICS INC
NASDAQ:ADMA (1/31/2025, 4:41:09 PM)
After market: 16.15 0 (0%)16.15
+0.05 (+0.31%)
The current stock price of ADMA is 16.15 USD. In the past month the price decreased by -5.83%. In the past year, price increased by 208.8%.
ADMA Latest News, Press Releases and Analysis
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
ADMA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.11 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.95B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About ADMA
Company Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 624 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Company Info
ADMA BIOLOGICS INC
465 State Route 17
Ramsey NEW JERSEY 07446 US
CEO: Adam S. Grossman
Employees: 624
Company Website: https://www.admabiologics.com/
Investor Relations: https://www.admabiologics.com/investors
Phone: 12014785552
ADMA FAQ
What is the stock price of ADMA?
The current stock price of ADMA is 16.15 USD.
What is the symbol for ADMA BIOLOGICS INC stock?
The exchange symbol of ADMA BIOLOGICS INC is ADMA and it is listed on the Nasdaq exchange.
On which exchange is ADMA stock listed?
ADMA stock is listed on the Nasdaq exchange.
Is ADMA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ADMA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ADMA.
Does ADMA stock pay dividends?
ADMA does not pay a dividend.
What is the Price/Earnings (PE) ratio of ADMA?
The PE ratio for ADMA is 57.68. This is based on the reported non-GAAP earnings per share of 0.28 and the current share price of 16.15 USD.
What is the Short Interest ratio of ADMA stock?
The outstanding short interest for ADMA is 5.99% of its float.
ADMA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ADMA. When comparing the yearly performance of all stocks, ADMA is one of the better performing stocks in the market, outperforming 96.54% of all stocks.
ADMA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ADMA. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability.
ADMA Financial Highlights
Over the last trailing twelve months ADMA reported a non-GAAP Earnings per Share(EPS) of 0.28. The EPS decreased by 354.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.8% | ||
| ROA | 17.44% | ||
| ROE | 29.38% | ||
| Debt/Equity | 0.44 |
ADMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ADMA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 502.12% and a revenue growth 64.76% for ADMA